media – Page 547 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups

After a string of announcements a few years back, there’s been few new, high-profile biotech startups taking shape in New York. But that quiet period might be coming to an end this morning with the arrival of Quentis Therapeutics, a cancer immunotherapy startup born from the lab of former Weill Cornell Medicine dean and immunologist Laurie Glimcher. The company makes its debut today with a $48 million Series A round.
- Source: Xconomy
- 541
- March 5, 2018
cancer immunotherapy Series
Cardiovascular Systems, Inc. and OrbusNeich Announce FDA Clearance of the First and Only 1.0mm Coronary Balloon in the U.S.

Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the OrbusNeich® 1.0mm Sapphire® II PRO coronary balloon.
- Source: Enhancedonlinenews
- 494
- March 5, 2018
artery disease New Approvals Sapphire
Ancon Medical Launches Human Trials in Search for Flu Biomarker

With its worldwide impact and mounting death toll, the 2017-2018 influenza season shows that the viral disease isn’t just a fever and the sniffles, but rather a dangerous disease that can spread rapidly between people. That’s why a leading healthcare technology company is pushing forward with trials that can help doctors and medical staff easily identify the disease early in the process through a simple breath test.
- Source: Cision
- 925
- March 5, 2018
flu influenza Researches
Philips to launch new version of HealthSuite with AI and analytics at HIMSS18

At HIMSS18, Philips plans to announce several new additions to its line of connected care products. A new management system called FocusPoint will help give hospitals more visibility into the performance of their patient monitoring technology.
- Source: MobiHealthNews
- 496
- March 5, 2018
AI Company Insight digital health
Siemens unveils new Cios Select intraoperative imaging device

The new Cios Select offers many features designed specifically for intraoperative imaging in orthopaedics, trauma surgery, urology, pain management, and peripheral vascular surgery. Credit: Siemens Healthineers.
- Source: medicaldevice-network
- 612
- March 5, 2018
Cios Select Company Insight Siemens
How HealthBot is providing healthcare for the unconnected

HealthBot, a healthcare start-up, aims to bring the best of medical services to people staying in remote locations, especially rural areas, through its technology platform.
- Source: Financial Express
- 492
- March 5, 2018
Company Insight digital health healthcare India Internet of Things
MeiraGTx Earns EMA PRIME Designation for Achromatopsia Gene Therapy Candidate

A new gene therapy to treat a debilitating eye disorder is one step closer to regulatory approval in Europe. Gene therapy company MeiraGTx said the European Medicines Agency granted Priority Medicines (PRIME) designation to its candidate A002 for treatment of achromatopsia.
- Source: biospace
- 414
- March 5, 2018
achromatopsia eye disorder New Approvals
Qualcomm Life signs deal with AlertWatch, PeriGen

Qualcomm Life announced an exclusive licensing agreement with AlertWatch, creator of an FDA-cleared intelligence care software that assists in the care of patients in the operating room. The deal will give Qualcomm Life the exclusive rights to sell AlertWatch, which the company plans to showcase at HIMSS 2018.
- Source: MobiHealthNews
- 568
- March 2, 2018
digital health FDA Market Views
Pear Therapeutics and Novartis Will Collaborate on Prescription-Strength Apps

Boston-based startup Pear Therapeutics will link with Novartis to develop prescription-strength digital interventions for schizophrenia and multiple sclerosis (MS).
- Source: HCANews
- 761
- March 2, 2018
Company Insight digital health mHealth Novartis
Powerful enzyme could make CRISPR gene-editing more versatile

Revamped Cas9 protein could work on more sites in the genome, and with fewer unwanted effects.
- Source: Nature.com
- 556
- March 2, 2018
CRISPR-Cas9 genome editing Researches

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.